RIA
ESPR

Realta Investment Advisors’s Esperion Therapeutics ESPR Stock Holding History

Realta Investment Advisors’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-750
Closed -$38K – 620
2019
Q4 		$38K Sell
750
-75
-9% -$3.37K 0.01% 738
2019
Q3 		$30K Hold
825
– – 0.01% 799
2019
Q2 		$38K Buy
825
+250
+43% +$11.7K 0.01% 738
2019
Q1 		$23K Buy
+575
New +$25.8K 0.01% 722

Other funds holding ESPR

BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Realta Investment Advisors's ESPR Position: Q1 2020 in Review

Realta Investment Advisors sold out of Esperion Therapeutics (ESPR) in Q1 2020, closing a stake of 750 shares — an estimated $38K sold.

Realta Investment Advisors first reported a position in ESPR in Q1 2019 and held it in 4 quarters. The position peaked at $38K in Q4 2019. 165 funds tracked by Wall St. Rank hold ESPR as of Q1 2020.

  • Realta Investment Advisors reported no remaining Esperion Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Realta Investment Advisors sold 750 Esperion Therapeutics shares in Q1 2020, an estimated $38K.
  • Realta Investment Advisors first reported a position in Esperion Therapeutics in Q1 2019 and held it in 4 quarters.
  • Realta Investment Advisors's Esperion Therapeutics position peaked at $38K in Q4 2019.
  • 165 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q1 2020.

Based on Realta Investment Advisors's 13F filing for Q1 2020, filed 23 Apr 2020.